
---
title: '金陵药业：琥珀酸亚铁片通过仿制药一致性评价'
categories: 
 - 金融
 - 证券时报网
 - 快讯
headimg: 'https://picsum.photos/400/300?random=6772'
author: 证券时报网
comments: false
date: Tue, 08 Feb 2022 16:57:00 GMT
thumbnail: 'https://picsum.photos/400/300?random=6772'
---

<div>   
<p>证券时报e公司讯，<a class="trsHotWords" href="https://info.stcn.com/dc/stock/?stockcode=SZ000919" style="color: #2f67d1;text-decoration: none;" code="000919" target="_blank">金陵药业</a>(000919)2月8日晚间公告，下属分公司<a class="trsHotWords" href="https://info.stcn.com/dc/stock/?stockcode=SZ000919" style="color: #2f67d1;text-decoration: none;" code="000919" target="_blank">金陵药业</a>股份有限公司南京金陵制药厂收到国家药监局核准签发的《药品补充申请批准通知书》，公司琥珀酸亚铁片通过仿制药质量和疗效一致性评价。琥珀酸亚铁片主要用于缺铁性贫血的预防和治疗。</p>

                  
</div>
            